In support, studies have shown that the T188I mutation in ITGB1 contributed to neoplasia by over-activating ERK/MAPK signaling [59], and mutations in ITGA2 were associated with an increased risk of prostate, oral, and breast cancers [60]. This evidence concerns the gene ITGA2 and breast carcinoma.